Table 1.
Clinical trials evaluating POEM for the management of achalasia.
| Authors | Study design |
Patients (n) |
Myotomy length; mean (range), cm |
Dysphagia score | Eckardt score |
LES pressure; mean (range), mm Hg |
GERD symptoms |
Follow-up; mean (range) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline; mean | Post-POEM; mean (n, %) | Baseline; mean | Post-POEM; mean (n, %) | Baseline | Post-POEM | ||||||
| Inoue et al. [13] | Single-center prospective |
17 | 8.1 (3–15) | 10 | 1.3 (17, 100%) |
N/A | N/A | 52.4 (14.2–80.5) |
19.8 (9.3–42.7) |
N/A | 5 (1–16) months |
| Swanström et al. [14] | Single-center prospective |
5 | 10 (10–13) | N/A | 0 or 1 (5, 100%) |
N/A | N/A | 36.5 (9.9– 39.8) |
N/A | N/A | 2 weeks |
| von Renteln et al. [15] | Single-center prospective |
16 | 12 (8–17) | N/A | N/A | N/A | ≤3 (15, 94%) | 27.2 | 11.8 | None | 3 months |
| Costamagna et al. [16] | Single-center prospective |
11 | 10.2 ± 2.8 | N/A | N/A | 7.1 | 1.1 (11, 100%) | 45.1 | 16.9 | None | 3 months |
| Chiu et al. [17] | Single-center prospective |
16 | 10.8 | 2 (range 0–2) |
0 (range 0-1) |
5.5 (range 0–8) |
0 (range 0–3) (16, 100%) |
43.6 ± 24.4 | 29.8 ± 22 | 1/16 (6.25%) |
176.5 (98–230) days |
| Hungness et al. [21] | Single-center retrospective |
18 | 9 (6–14) | N/A | N/A | 7 (range 5–12) |
1 (range 0–9) (18, 100%) |
19 (7–51) | 9 (0–23) | 4/18 (22%) based on GerdQ score ≥7 | 6 (1–18) months |
| Zhou et al. [24] | Single-center prospective |
12 | 10.1 (8–13) | N/A | N/A | ≤3 (11, 91.7%) |
29.4 (23.5–40.2) |
13.5 (8.6–22.5) |
1/12 (8.3%) | 10.4 (5–14) months | |
| Verlaan et al. [18] | Single-center prospective |
10 | N/A | N/A | N/A | 8 (range 4–8) |
1 (range 0-1) (10, 100%) |
20.5 (15.8–24.3) |
6.8 (4.0–12.0) |
3/10 (30%) | 3 months |
| Minami et al. [20] | Single-center retrospective |
28 | 14.4 (10–18) | N/A | N/A | 6.7 (range 2–12) |
0.7 (range 0–3) (28; 100%) |
71.2 (35.8–119.0) |
21.0 (6.7–41.0) |
6/28 (21.4%) | 16 (3–28) months |
| Lee et al. [19] | Single-center prospective | 13 | 8.5 (6–13) | N/A | N/A | 6.4 (range 4–10) |
0.4 (range 0–2) (13; 100%) |
30.3 (14.4–57.1) |
15.3 (9.6–22.3) |
N/A | 6.9 (1–14) months |
| Von Renteln et al. [22] | Multicenter prospective | 70 | 13 (5–13) | N/A | N/A | ≤3 (68, 97%) at 3 months |
27.6 (24.2–31.0) |
8.9 (7.3–10.5) |
37% | 10.1 (3–12) months | |
N/A: not available.